CIK 0000072444 · Accelerated filer<br>Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 591212264
- Phone
- (650) 550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-08 | Lee Phillip E Chief Financial Officer | Shares withheld for taxes | −35,151 | $0.71 | $25K | 157,751 |
| 2023-12-08 | Cummings James F. Chief Medical Officer | Shares withheld for taxes | −31,409 | $0.71 | $22K | 248,058 |
| 2023-12-08 | Berg Edward B SVP, General Counsel | Shares withheld for taxes | −33,752 | $0.71 | $24K | 189,926 |
| 2023-06-26 | Watson W. Mark Director | Grant or award | +7,375 | 42,125 | ||
| 2023-06-26 | Watson W. Mark Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2023-06-26 | HERON ELAINE J Director | Grant or award | +6,922 | 24,566 | ||
| 2023-06-26 | HERON ELAINE J Director | Grant or award · Stock Option (right to buy) | +41,510 | 41,510 | ||
| 2023-06-26 | Yedid Robert A. Director | Grant or award | +7,375 | 18,490 | ||
| 2023-06-26 | Yedid Robert A. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2023-06-26 | Wheadon David E. Director | Grant or award | +7,375 | 14,750 | ||
| 2023-06-26 | Wheadon David E. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2023-06-26 | Finney Michael J. Director | Grant or award | +7,375 | 670,840 | ||
| 2023-06-26 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +44,224 | 44,224 | ||
| 2023-06-12 | Lee Phillip E Chief Financial Officer | Grant or award | +22,500 | 192,902 | ||
| 2023-06-12 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (right to buy) | +102,500 | 102,500 | ||
| 2023-03-28 | Cummings James F. Chief Medical Officer | Shares withheld for taxes | −3,267 | $0.75 | $2K | 349,821 |
| 2023-03-28 | Tucker Sean SVP, Chief Scientific Officer | Shares withheld for taxes | −3,683 | $0.75 | $3K | 373,630 |
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award | +45,000 | 113,750 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award | +56,652 | 170,402 | ||
| 2023-03-17 | Lee Phillip E Chief Financial Officer | Grant or award · Stock Option (right to buy) | +205,000 | 205,000 |
Page 7 of 10 · 198 trades